Kabushiki Kaisha Yakult Honsha

Teikoku Hormone Mfg. Co., Ltd.

Shusuke Hashimoto

Masato Nagaoka

Takeshi Matsuzaki

Teruo Yokokura

Ryuta Yamazaki

Ritsuo Aiyama

Hideyuki Shibata

Takashi Ikeda

Seigo Sawada

Hiroshi Hatano

Takashi Yaegashi

Tomio Furuta

Tsunekazu Watanabe

Yoshiyuki Shishido

Yoshikazu Sugimoto

Itsuko Kimura

Yukiko Nishiyama

Oh Yoshida

Masashi Sakai

Koji Nomoto

Tomoyuki Sako

Kunio Kado

Kisaku Shimura

Tsuneo Matsumoto

Hiroshi Sansawa

Osamu Matsuo

Masaharu Onoue

Tetsuya Terasaki

Shuichi Tanabe

Masayoshi Furushiro

Itsuko Takagi

A novel compound having an excellent NF&#x3ba;B inhibitory effect is provided and specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, Rrepresents a hydrogen atom, a lower alkyl group, a lower alkyloxy group, or a halogen atom; Rrepresents a hydroxyl group, or a lower alkyloxy group; Rrepresents a hydrogen atom, a lower alkyl group, or a halogen atom; Rrepresents a hydrogen atom or a lower alkyloxy group; Rrepresents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with Ror an isopropylidenedioxy group formed together with R; Rrepresents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with Ror an isopropylidenedioxy group formed together with R; Rrepresents a hydrogen atom or a lower alkyl group; and Rrepresents a hydrogen atom, a hydroxyl group, an amino group, or a lower alkylcarbonyloxy group (excluding the case where R, R, Rand Rare hydrogen atoms, Rand Rare hydroxyl groups, and Rand Rare methoxy groups). 

Phenanthroindolizidine compound and NF&#x3ba;B inhibitor containing same as active ingredient

A breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative or a salt thereof.

BCRP/ABCG2 inhibitor

A novel compound having an excellent NF&#x3ba;B inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: 

Phenanthroindolizidine derivative and NF&#x3ba;B inhibitor containing same as active ingredient

An antibacterial agent showing a high affinity forand having an antibacterial effect specific toThe agent has a chemical structure wherein an antibacterial substance is bonded to a sulfated polysaccharide or an oligosaccharide prepared by partial decomposition of the sulfated polysaccharide. Preferable embodiments are those having the chemical structure represented by Y&#x2014;OCH(AHNHR)or Y&#x2014;BHNHR, wherein Y represents a sulfated polysaccharide or an oligosaccharide prepared by partial decomposition of the sulfated polysaccharide; A a carbon derived from aldehyde group occurring through the reduction of the reduced end sugar of Y and subsequent oxidation of the resulting product with an oxidant; B a carbon derived from the aldehyde group at the reduced end sugar of Y; R an antibacterial substance with a primary amino group or with an amino group introduced therein or represents an antibacterial substance derivative prepared by bonding an antibacterial substance through a spacer to the carbon A or the carbon B; and n=1 or 2.

Antibacterial agents and process for producing the same

The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (&#x2014;NHCOCHgroup); a cyano group (&#x2014;CN group); a formyl group (&#x2014;CHO group), &#x2014;COOR(Ris hydrogen or C1-C4 alkyl), &#x2014;O(CH)COOR(n=1&#x2212;7: Ris hydrogen or C1-C4 alkyl), &#x2014;OOCCHCHCOOR(Ris hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., &#x2014;OP(O) (OH)) or a salt thereof, a sulfate group (i.e., &#x2014;OSOH) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

[object Object]

Oligosaccharide derivatives and process for producing the same

Peptides and nootropic agent

Specific cyclooxygenase 2 inhibitor and anti-inflammatory agent

A diarylheptanoide derivative of the following formula (1), ##STR1## and a drug composition comprising this compound, such as a 5-lipoxygenase inhibitor, an antiinflammatory agent, and the like. The diarylheptanoide derivative (1) is effective for treating and preventing various inflammatory diseases due to its strong 5-lipoxygenase inhibiting effect.

Diarylheptanoide derivative and pharmaceutical composition comprising

An antiulcer agent effective on prevention of ulceration and acceleration of healing of ulcers and processes for preparing the same are disclosed. The antiulcer agent comprises rhamnan (a homopolysaccharide), rhamnose or a rhamnose oligomer as an active ingredient. Rhamnan is prepared by separating rhamnan sulfate from rhamnan sulfate-containing algae and desulfurating the rhamnan sulfate. Rhamnan oligomers are prepared by hydrolyzing rhamnan obtained by desulfuration of rhamnan sulfate or by hydrolyzing microbial cells of a Bifidobacterium or polysaccharides separated therefrom.

Antiulcer agent and process for preparing the same

An antitumor agent is provided by including, as an active ingredient, a polysaccharide-glycan complex obtained by treating a Gram-positive bacteria such as lactic acid bacteria and Bifidobacterium strains with a cell wall lytic enzyme produced by a bacterium belonging to the genus Achromobacter. The polysaccharide-glycan complex has no toxicity and causes no side effect. Being water-soluble, it is easily formulated into any arbitrary dose form, such as an injectable solution. It can easily be prepared from an easily available starting material.

Antitumor polysaccharide-glycan complexes

Thrombolytic peptide, production thereof, and thrombolytic agent

Growing community of inventors

Tokyo, Japan

Shusuke Hashimoto